Journal of Leukemia
Open Access

Pham HQ

Publications

• Research Article
  Utilization of Next-Generation Deep Sequencing to Analyze BCR-ABL1 Kinase Domain Mutation for Imatinib-Resistant Chronic Myeloid Leukemia Patients in Vietnam
  Author(s): Duong CQ, Nguyen C, Nguyen TT, Nguyen LV, Pham HQ, Trinh HTT, Tran HC, Le TQ, Pham HT, Hong TH, Nguyen TH, Truong HN, Bach KQ and Nguyen TADuong CQ, Nguyen C, Nguyen TT, Nguyen LV, Pham HQ, Trinh HTT, Tran HC, Le TQ, Pham HT, Hong TH, Nguyen TH, Truong HN, Bach KQ and Nguyen TA
  
  Background: Chronic myeloid leukemia is a clonal myeloproliferative neoplasm, characterized by the presence of chromosomal translocation t(9; 22)(q34; q11). This is found in over 95% of the cases and results in the BCR-ABL1 fusion protein with high tyrosine kinase activity. During the last decades, imatinib and other generations of tyrosine kinase inhibitor have been used effectively for target therapy of the disease. However, many of the drug resistant cases have been reported recently, due to the mutation within kinase domain of the BCR-ABL1 fusion gene. In order to provide further information about this incidence, we performed a retrospective study of 141 imatinib-resistance chronic myeloid leukemia patients to analyze kinase domain mutation by deep sequencing. Another group of 20 untreated patients were added as control. Methods: RNA from bone marrow cells were extracted and follo.. View More»
  DOI: 10.4172/2329-6917.1000235

  Abstract PDF

Relevant Topics